BioAge Labs Past Earnings Performance
Past criteria checks 0/6
BioAge Labs's earnings have been declining at an average annual rate of -17.9%, while the Pharmaceuticals industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 133.1% per year.
Key information
-17.87%
Earnings growth rate
70.64%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 133.06% |
| Return on equity | -29.63% |
| Net Margin | -896.11% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
BioAge Labs: Why Getting Into The Brain Might Be A Headache For Investors
Jan 16Is BioAge Labs (NASDAQ:BIOA) Weighed On By Its Debt Load?
Jul 15
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
Jan 13BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
Sep 30Revenue & Expenses Breakdown
How BioAge Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 9 | -81 | 28 | 0 |
| 30 Sep 25 | 6 | -76 | 27 | 0 |
| 30 Jun 25 | 4 | -79 | 25 | 0 |
| 31 Mar 25 | 1 | -71 | 22 | 0 |
| 31 Dec 24 | 0 | -71 | 19 | 0 |
| 30 Sep 24 | 0 | -71 | 17 | -24 |
| 30 Jun 24 | 0 | -62 | 15 | -17 |
| 31 Mar 24 | 0 | -66 | 15 | -8 |
| 31 Dec 23 | 0 | -64 | 15 | 0 |
Quality Earnings: BIOA is currently unprofitable.
Growing Profit Margin: BIOA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BIOA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BIOA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.6%).
Return on Equity
High ROE: BIOA has a negative Return on Equity (-29.63%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 15:57 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioAge Labs, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |
| Salveen Richter | Goldman Sachs |